XOMA Royalty Corporation (XOMA)

In the past six months, XOMA Royalty Corp. rebranded from XOMA Corporation on July 10, 2024. The company reported $29.6 million in cash receipts in the first half of 2025, including an $8.1 million milestone payment from Viracta Therapeutics, Inc., and a $9 million milestone payment following the FDA's approval of OJEMDA™. XOMA Royalty and LAVA Therapeutics announced an amendment to a purchase agreement in October 2025, and Mural Oncology shareholders approved the proposed acquisition by XRA 5 Corp. Other acquisitions included Turnstone Biologics and HilleVax, and the purchase of mezagitamab royalty and milestone rights from BioInvent International. XOMA Royalty also declared quarterly preferred stock dividends in September 2025.

XOMA Royalty Corporation's business model does not typically experience traditional product demand seasonality. Instead, its revenue streams are tied to the development progress and commercial sales of its partners' drug candidates, influenced by the timelines of drug development, clinical trial results, regulatory approvals, and the commercial launch of therapeutic products.

XOMA Royalty Corporation operates as a biotechnology royalty aggregator, primarily in the United States and the Asia Pacific region, acquiring economic rights to future milestone and royalty payments from partnered therapeutic candidates, focusing on early to mid-stage clinical assets with commercial sales potential. The company's portfolio includes over 120 assets across more than 11 therapeutic categories, many of which are licensed to large-cap partners. XOMA was formerly known as XOMA Corporation and officially changed its name to XOMA Royalty Corporation in July 2024.

XOMA Royalty Corporation is headquartered in Emeryville, California, United States, with operations and a portfolio of economic rights extending across the United States and the Asia Pacific region.

XOMA Royalty Corporation's brand reputation is characterized by strategic growth and successful business development. The company's rebranding solidified its identity as a dedicated biotech royalty aggregator. Recent positive events include the receipt of significant milestone payments and the expansion of its portfolio through several acquisitions, demonstrating a commitment to growth and diversification of its royalty streams.

Institutional investors hold 46% of XOMA Royalty Corporation, while hedge funds account for 22%. The top five shareholders collectively own 53% of the outstanding shares. BVF Partners L.P. is the largest shareholder with 22% ownership. Owen Hughes, the CEO, owns 0.5% of the company's shares.